Abstracts tagged "fibrosis"

Abstract Number: 1044 • 2019 ACR/ARP Annual Meeting
TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype in SSc?
Peter Wermuth¹ and Sergio Jimenez ¹, ¹Jefferson Institute of Molecular Medicine and Division of Connective Tissue Diseases, Thomas Jefferson University, Philadelphia, PA, Philadelphia, PA
Background/Purpose: Extracellular vesicles (EV) are a diverse assortment of lipid bilayer-bound vesicles of various sizes and origin. Exosomes are a subset of EV arising from…
Abstract Number: 1049 • 2019 ACR/ARP Annual Meeting
Induction of a Profibrotic Phenotype in Normal Dermal Fibroblasts by Expression of PIM1 Kinase and Demonstration of Antifibrotic Effects of Inhibition of PIM Kinases in Systemic Sclerosis Dermal Fibroblasts
Danielle Pomante ¹, Sergio Jimenez ² and Sonsoles Piera-Velazquez¹, ¹Thomas Jefferson University, Philadelphia, PA, ²Jefferson Institute of Molecular Medicine and Division of Connective Tissue Diseases, Thomas Jefferson University, Philadelphia, PA, Philadelphia, PA
Background/Purpose: There is an urgent unmet need for effective therapeutic approaches for Systemic Sclerosis (SSc), a systemic autoimmune disease characterized by progressive fibrosis of skin…
Abstract Number: 1058 • 2019 ACR/ARP Annual Meeting
Inhibition of Histone Readers Bromodomain and Extraterminal Domain Proteins Alleviates Scleroderma Fibrosis
Sirapa Vichaikul ¹, Phillip Campbell ², M. Asif Amin ³, Jeffrey H. Ruth ³, Dallas Rohraff ¹, David Fox ⁴, Dinesh Khanna ⁵, Amr Sawalha ⁶ and Pei-Suen Tsou³, ¹University of Michigan, Ann Arbor, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI, ⁵Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor, ⁶University of Pittsburgh & University of Michigan, Pittsburgh, PA
Background/Purpose: Epigenetic regulation, including histone acetylation, plays an important role in scleroderma (SSc) fibrosis. The binding of the bromodomain and extra-terminal domain proteins (BRDs) to…
Abstract Number: 1061 • 2019 ACR/ARP Annual Meeting
PI3K-Akt Pathway Plays a Crucial Role in Production of Collagen in Fli1 Deficient Condition and Its Inhibitor Has the Therapeutic Potential in Treating Fibrosis
Yuko Ota¹, Atsushi Kitani ² and Warren Strober ², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Mucosal Immunity Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis of the skin and internal organs. Previous studies have shown that dermal fibroblast…
Abstract Number: 1066 • 2019 ACR/ARP Annual Meeting
Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis
Christopher Denton ¹, Shiwen Xu ², Sue Verma ³ and Voon Ong⁴, ¹University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ²University College London, London, United Kingdom, ³Leadiant Biosciences, London, United Kingdom, ⁴UCL Medical School, Royal Free Campus, London
Background/Purpose: Altered generation of adenosine from extracellular nucleotides by ectonucleotidases may orchestrate chronic injury responses and promote fibrosis via the adenosine A2A receptor (ADORA2A). We…
Abstract Number: 1073 • 2019 ACR/ARP Annual Meeting
Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis
Angela Tam¹, Lauren Reinke-Breen ², Glenda Trujillo ², Shiwen Xu ¹, Christopher Denton ³, David Abraham ¹, Gabor Jarai ² and Voon Ong ⁴, ¹University College London, London, United Kingdom, ²Bristol-Myers Squibb, Pennington, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁴UCL Medical School, Royal Free Campus, London
Background/Purpose: Chronic inflammation may modulate the balance of classical, intermediate and non-classical monocyte subsets (defined by CD14/CD16 expression)1. Monocytes are heterogeneous and subsets can be…
Abstract Number: 1231 • 2019 ACR/ARP Annual Meeting
Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase
Naomi Schlesinger¹, Anthony Yeo ² and Peter Lipsky ³, ¹Division of Rheumatology, Department of Medicine, Rutgers, The State University of New Jersey, New Brunswick, NJ, ²Horizon Therapeutics plc, Lake Forest, IL, ³AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Hyperuricemia is associated with non-alcoholic fatty liver disease (NAFLD) (Yang C et al. PlosOne2017; 12:e0177249; Jaruvongvanich V et al. Eur J Gastroenterol Hepatol 2017;…
Abstract Number: 2429 • 2019 ACR/ARP Annual Meeting
Zipcode-Binding Protein 1 (ZBP1) Facilitates Ro60 Surface Translocation, Cellular Growth and Autoimmune Sequelae
Francis DiDonato¹, Jill Buyon ¹ and Robert Clancy ¹, ¹NYU School of Medicine, New York
Background/Purpose: Despite the strong association of maternal anti-Ro60 autoantibodies in the development of SS, Neonatal Lupus (NL) and scLE, understanding causality is challenging given that…
Abstract Number: 2748 • 2019 ACR/ARP Annual Meeting
Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk
Elena Pachera¹, Shervin Assassi ², Gloria Salazar ³, Mojca Frank-Bertoncelj ⁴, Jörg Distler ⁵, Gabriela Kania ⁶ and Oliver Distler ⁷, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Zurich, Switzerland, ²Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ³University of Texas McGovern Medical School, Houston, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁶Centre of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Long noncoding RNAs (lncRNAs) are an emerging class of noncoding transcripts involved in the regulation of gene expression in health and disease. LncRNAs function…
Abstract Number: 2808 • 2019 ACR/ARP Annual Meeting
Linking Toll-Like Receptor Signaling and Type I Interferons to Inflammation and Fibrosis in a Macrophage/Fibroblast Model of Congenital Heart Block
Miao Chang¹, Robert Clancy ¹ and Jill Buyon ¹, ¹NYU School of Medicine, New York
Background/Purpose: Since one of the strongest associations with antibodies (abs) to SSA/Ro (Ro60) is the development of congenital heart block (CHB), this model provides an…
Abstract Number: 374 • 2019 ACR/ARP Annual Meeting
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Eric Matteson¹, Clive Kelly ², Jörg Distler ³, Anna Maria Hoffmann-Vold ⁴, James Seibold ⁵, Shikha Mittoo ⁶, Oliver Distler ⁷, Rainer-Georg Goeldner ⁸, Rozsa Schlenker-Herceg ⁹, Susanne Stowasser ¹⁰, Manuel Quaresma ¹⁰ and Kevin Flaherty ¹¹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ⁶University Health Network, Toronto, Ontario, Canada, Toronto, Canada, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
Abstract Number: 384 • 2019 ACR/ARP Annual Meeting
Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease
Connie Lam ¹, Stephen Bloom ² and Alberta Hoi³, ¹School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia, ³School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia
Background/Purpose: The assessment of liver stiffness using liver elastography (Fibroscan) has facilitated early diagnosis of hepatic fibrosis in patients with chronic liver disease, but its…
Abstract Number: 114 • 2018 ACR/ARHP Annual Meeting
Antifibrotic Regulation By Response Gene to Complement 32 Protein
Sergei Atamas, Violeta Rus, Virginia Lockatell, Horea Rus and Irina Luzina, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Pulmonary fibrosis is a serious problem in patients with scleroderma lung disease (SLD). Better therapies for pulmonary fibrosis are urgently needed. Identification of new…
Abstract Number: 117 • 2018 ACR/ARHP Annual Meeting
Hypomorphic A20 Expression Modulates Fibrosis Susceptibility: Implications for Systemic Sclerosis?
Swati Bhattacharyya¹, Wenxia Wang², Brian M. Jeong², Hiam Abdala-Valencia³, Roberta Goncalves Marangoni¹, Sergejs Berdnikovs Ph.D.⁴ and John Varga¹, ¹Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Medicine, Northwestern University, Chicago, IL
Background/Purpose: Mutiple organ fibrosis, a hallmark of systemic sclerosis (SSc), remains poorly understood. Recent GWAS have uncovered consistent genetic linkage between TNFAIP3, encoding the ubiquitin-editing…
Abstract Number: 118 • 2018 ACR/ARHP Annual Meeting
Pharmacological Inhibition of JAK/STAT Signaling By Tofacitinib Prevents Experimental Organ Fibrosis: Novel Therapy for Systemic Sclerosis
Swati Bhattacharyya¹, Wenxia Wang², Jun Wei³ and John Varga¹, ¹Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Northwestern University, chicago, IL
Background/Purpose: Synchronous fibrosis in systemic sclerosis (SSc) leads to failure of the skin, lungs and other organs, and has no effective treatments. Myofibroblast activation underlies…

1
2
3
…
8
Next Page »